Zydus Lifesciences Limited Earnings Summary — Q4 FY2026

• Revenue for the quarter grew 16.2% YoY to ₹7,587 Cr, marking a significant acceleration in scale.
• Operating Profit Margin (OPM) increased to 34%, reflecting strong operating leverage and a move toward high-margin therapies.
• Net profit saw a healthy recovery to ₹1,341 Cr despite a sharp rise in quarterly depreciation charges to ₹508 Cr.
• Other Income was negative at -₹263 Cr in the latest quarter, acting as a drag on bottom-line performance.
• The balance sheet shows a massive increase in borrowings, reaching ₹12,496 Cr by March 2026, compared to ₹3,213 Cr in the prior year.
• Interest expenses rose sharply to ₹123 Cr in Q4, reflecting the impact of the increased debt load.
• The company maintains a high promoter holding of 75%, indicating strong alignment between leadership and shareholders.

Management is pivoting toward chronic therapies and complex generics in the domestic market to navigate global generic commoditization.

Improving

Robust revenue growth and peak operating margins outweigh the concerns regarding the sudden increase in corporate debt.

The outlook remains healthy driven by a 32% three-year profit CAGR. Success in biosimilars and chronic segments is expected to sustain high margins, though regulatory hurdles at USFDA-monitored facilities remain a key monitorable.